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Abstract
A balanced omega-6/omega-3 polyunsaturated fatty acid (PUFA) ratio has been linked to health benefits and the
prevention of many chronic diseases. Current dietary intervention studies with different sources of omega-3 fatty acids
(omega-3) lack appropriate control diets and carry many other confounding factors derived from genetic and environmental
variability. In our study, we used the fat-1 transgenic mouse model as a proxy for long-term omega-3 supplementation to
determine, in a well-controlled manner, the molecular phenotype associated with a balanced omega-6/omega-3 ratio. The
fat-1 mouse can convert omega-6 to omega-3 PUFAs, which protect against a wide variety of diseases including chronic
inflammatory diseases and cancer. Both wild-type (WT) and fat-1 mice were subjected to an identical diet containing 10%
corn oil, which has a high omega-6 content similar to that of the Western diet, for a six-month duration. We used a multi-
platform lipidomic approach to compare the plasma lipidome between fat-1 and WT mice. In fat-1 mice, an unbiased
profiling showed a significant increase in the levels of unesterified eicosapentaenoic acid (EPA), EPA-containing cholesteryl
ester, and omega-3 lysophosphospholipids. The increase in omega-3 lipids is accompanied by a significant reduction in
omega-6 unesterified docosapentaenoic acid (omega-6 DPA) and DPA-containing cholesteryl ester as well as omega-6
phospholipids and triacylglycerides. Targeted lipidomics profiling highlighted a remarkable increase in EPA-derived diols
and epoxides formed via the cytochrome P450 (CYP450) pathway in the plasma of fat-1 mice compared with WT mice.
Integration of the results of untargeted and targeted analyses has identified a lipidomic biosignature that may underlie the
healthful phenotype associated with a balanced omega-6/omega-3 ratio, and can potentially be used as a circulating
biomarker for monitoring the health status and the efficacy of omega-3 intervention in humans.
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Introduction
Most Western diets are deficient in omega-3 polyunsaturated
fatty acids (PUFAs) and abundant in omega-6 PUFAs [1]. Current
nutritional research shows that a diet enriched in omega-3s offers
health benefits and anti-inflammatory properties and that an
excess of omega-6s might contribute to the pathogenesis of many
chronic diseases, including cardiovascular, autoimmune and
Alzheimer’s diseases [2–10]. The imbalance between omega-6s
and omega-3s is largely the result of the traditional reliance of
Western diets on vegetables oils such as corn, soybean, safflower,
and sunflower. These oils are enriched in omega-6 PUFAs, such as
linoleic acid (LA), which can be metabolized in animals and
humans to form longer chain fatty acids such as di-homo-gamma-
linolenic acid (DGLA), docosapentaenoic acid (omega-6 DPA),
and arachidonic acid (AA) are (Figure 1). At the same time,
Western diets are lacking in leafy green vegetables, which are
enriched in the omega-3 fatty acid, alpha-linolenic acid (ALA), and
in oily fish, which contain the longer-chain omega-3 PUFAs such
as eicosapentaenoic acid (EPA), omega-3 DPA, and docosahex-
aenoic acid (DHA) (Figure 1).
The human body cannot synthesize PUFAs de novo and must
rely entirely on dietary intake for these essential nutrients. Also, it
cannot interconvert between omega-6 and omega-3 fatty acids.
The PUFAs, once absorbed in the intestines, are then transported,
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via the bloodstream, to all tissues. They can be found as
unesterified fatty acids or esterified to complex lipids (e.g.,
phospholipids, cholesteryl esters and triacylglycerols) and can be
metabolized into bioactive species (e.g., oxylipins) (Figure 1).
Hundreds of small molecules have been identified as metabolites of
these few omega-3 and omega-6 precursors in human tissue. Yet, it
is the overall balance between omega-3s and omega-6s that seems
to modulate many biological processes including the relaxation
and contraction of smooth muscle tissue, blood coagulation, and –
significantly – inflammation [11–13].
Although much research demonstrates a potentially important
relationship between PUFA intake and the risk of disease, it
remains challenging in current dietary intervention studies to
accurately evaluate the impact of increased intake of omega-3s by
food or supplementation. A frequently confounding factor is the
variability inherent in studies of control diets. A different
nutritional value may accompany such diets compared with a
diet enriched in omega-3– a different composition of fatty acids,
for example. Other frequent issues relate to the chemical nature,
source, and dose of the omega-3 used in the dietary intervention
studies. These issues include the mixed use of the different types of
omega-3s, such as EPA and DHA, or the different forms of omega-
3s, such as triacylglycerols, phospholipids, or ethyl esters.
Furthermore, dietary intervention studies in humans are often
associated with high individual genetic and environmental
variability [14]. All of these factors militate against an accurate
evaluation of the biological effects of omega-3s, and no molecular
markers of omega-3 intake currently exist.
In 2004, the fat-1 transgenic mouse model was developed to
eliminate many of the confounders inherent in omega-6/omega-3
research [15]. The mouse was engineered to carry the C. elegans fat-
1 gene, which can add a double bond into an unsaturated fatty-
acid hydrocarbon chain, thus converting omega-6 to omega-3 fatty
acids (Figure 1) [15]. Though the mice are not exposed to an
omega-3 diet, this conversion results in an abundance of omega-3
and a reduction in omega-6 fatty acids in their organs. The
resulting omega-6/omega-3 fatty acid profile has also been shown
to be comparable to those obtained by dietary supplementation
[16]. The animals therefore provide a controlled approach for
evaluating the effects of a balanced omega-6/omega-3 ratio, one
that does not introduce the confounding factors that result from
enforcing different test diets. To date, the fat-1 transgenic mouse
model has been widely used, and has demonstrated that balancing
the omega-6/omega-3 ratio can protect against a wide variety of
diseases, including chronic inflammatory diseases and cancer [3].
However, the molecular mechanisms underlying these beneficial
effects remain to be fully elucidated.
In the present study, we used a multi-platform lipidomic
approach to compare the molecular phenotype of fat-1 and WT
mice exposed for six months to an identical high-omega-6 diet in
order to identify the biosignature involved in the health benefits
associated with a balanced omega-6/omega-3 tissue ratio.
Figure 1. Overview of the omega-6 and omega-3 PUFAs metabolism. Diet-derived omega-6 linoleic acid (LA) and omega-3 alpha-linolenic
acid (ALA) are transformed into longer chains PUFAs by the sequential action of desaturases and elongases. PUFAs can be found in blood as
unesterified fatty acids, esterified to more complex lipids such as cholesteryl esters and phospholipids, or converted into the oxygenated metabolites
oxylipins. The figure shows chemical structures of fatty acids and derivatives highlighted in our study.
doi:10.1371/journal.pone.0096221.g001
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Materials and Methods
Materials
All chemicals were purchased from Sigma-Aldrich (Seelze,
Germany) and were of analytical grade or higher purity. Lipid
standards were purchased from Avanti Polar Lipids (Alabaster,
Alabama USA), Cayman Chemical (Ann Arbor, Michigan USA),
Biomol (Plymouth Meeting, Pennsylvania USA), and Larodan
Fine Chemicals (Malmo¨, Sweden). For solid-phase extraction, 96-
well, Waters Oasis HLB plates (60 mg) were obtained from Waters
Corporation (Milford, Massachusetts USA).
Animals and sample collection
Transgenic fat-1 C57BL/6J mice were generated as previously
described [15]. Only heterozygous female mice, aged 6 months,
were used in this study. The mice were fed an identical diet rich in
omega-6 PUFA and low in omega-3 PUFA (Catalog #1812692,
Test Diet, Richmond, Indiana USA), a modification of the Test
Diet AIN-76A semi-purified diet 58B0, with 10% total corn oil.
Both wild type and fat-1 mice were fed the same diet since weaning
until the mice were sacrificed. The diet components and fatty acid
composition of the diet are listed in Table S1. The animals were
phenotyped according to their omega-6 and omega-3 PUFA
profiles, as determined by gas chromatography [17]. For the
experiments described, WT and fat-1 littermates were used (n = 5).
At approximately 6 months of age, all mice underwent 18 hours of
fasting and were afterward euthanized by means of carbon
dioxide. Total blood volume was immediately collected using
cardiac puncture, and the blood was retained on ice. Whole-blood
samples were centrifuged at 1,0006g for 15 min at 4uC. Plasma
was transferred to a clean polypropylene tube and centrifuged at
10,0006g for 10 min at 4uC. Aliquots of the samples were drawn
and stored at 280uC until assayed. All animal procedures were
performed in accordance with guidelines prescribed by the
Massachusetts General Hospital (MGH) Animal Committee and
with Institutional Animal Care and Use Committee (IACUC) for
MGH approval (Protocol #2010N000038). All efforts possible
were made to minimize animal suffering. Animal investigations
conformed to the Public Health Policy on Humane Care and Use
of Laboratory Animals.
Lipid extraction from mouse plasma
Total lipids were extracted from 10 mL of plasma after protein
precipitation with 490 mL of isopropanol (IPA) spiked with the
following internal standard: d8 arachidonic acid, cholesterol-d7,
C19:0-cholesteryl ester, trinonadecenoin, 1,2-dimyristoyl-sn-gly-
cero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phos-
phocholine, 1-heptadecenoyl-2-hydroxy-sn-glycero-3-phospho-
choline. Samples were vortex mixed, incubated at 4uC for 30
min, and centrifuged at 10,0006g and 4uC for 10 min.
Supernatant was then transferred to mass-spectrometry vials for
further analysis. Extraction of oxylipins was performed as
previously described [18]. Briefly, after thawing on ice, 50 mL of
plasma samples were treated immediately with antioxidants
(0.2 mg butylated hydroxytoluene (BHT/EDTA)) and spiked with
the following internal standards: 6k-PGF1a-d4, TXB2-d4, PGF2a-
d4, PGE2-d4, PGD2-d4, LTE4-d3, LTB4-d4, 12,13 diHOME-d4,
9,10-diHOME-d4, 14,15-DiHETrE-d11, 15-deoxy-d-12,14-PGJ2-
d4, 20-HETE-d6, 9S-HODE-d4, 12S-HETE-d8, 5S-HETE-d8, 5-
oxo-ETE-d7. Plasma samples were loaded onto the solid-phase
extraction plate and then eluted with 1.5 mL ethyl acetate, after
wetting the plate wells with 0.5 mL methanol. The eluent was
reduced under nitrogen and subsequently reconstituted in a 50-mL
solution of methanol and acetonitrile (1:1) containing 100 nM 1-
cyclohexyluriedo-3-dodecanoic acid, a quality marker for the
analysis.
Liquid Chromatography Mass Spectrometry
Total lipid analysis was performed with IonKey/MS system
comprised of an ACQUITY UPLC M-Class, the ionKey source
and an iKey CSH C18 130 A˚, 1.7 mm particle size, 150 mm
6100 mm column (Waters Corporation, Milford, Massachusetts,
USA) coupled to a Synapt G2-S or Xevo TQ-S mass spectrometer
(Waters Corporation, Manchester, UK). The capillary voltage was
2.8 kV and the source temperature 110uC. Injections were 0.5 mL
using partial-loop mode with a column temperature of 55uC and
flow rate of 3 mL/min. Mobile phase A consisted of acetonitrile/
water (60/40) with 10 mM ammonium formate +0.1% formic
acid. Mobile phase B consisted of IPA/acetonitrile (90/10) with
10 mM ammonium formate +0.1% formic acid. The gradient was
programmed as follows: 0.0–2.0 min from 40% B to 43% B, 2.0–
2.1 min to 50% B, 2.1–12.0 min to 99% B, 12.0–12.1 min to 40%
B, and 12.1–14.0 min at 40% B. For the untargeted analyses, a
mass range of 50–1500 m/z was selected in both positive and
negative electrospray ionization.
Oxylipins were analyzed using UPLC (Waters Corporation,
Milford, Massachusetts USA) coupled to electrospray ionization
on a Xevo TQ-S mass spectrometer (Waters Corporation,
Manchester, UK). The auto sampler was cooled to 10uC. For
each analysis, 3 mL of sample was injected on a BEH C18 1.7 mm,
2.16100 mm column (Waters Corporation, Milford, Massachu-
setts, USA) using a flow rate of 0.6 mL/min at 40uC. Mobile
phases were composed as follows: A = 0.1% acetic acid, and
B = 90:10 v/v acetonitrile/IPA (0.00–1.00 min from 25% B to
33% B, 1.00–8.00 min B to 95%, 8.00–8.50 min to 95% B, 8.51–
10.00 min to 25% B). Electrospray ionization was performed in
the negative-ion mode applying a capillary voltage of 2 kV, a
source temperature of 120uC, a desolvation gas temperature of
350uC, a desolvation gas flow of 650 L/h, a cone-gas flow of
150 L/h, a collision voltage of 15 V, and a cone voltage of 35 V.
Oxylipins were detected using MRM transitions optimized using
synthetic standards (Table S2). Limits of quantification were in the
lower pM range.
Data Processing and Analysis
For the untargeted lipidomic approach, a combination of
analysis of the variance (ANOVA) and multivariate statistics,
including principal component analysis (PCA) and partial, least-
squares discriminant analysis (PLS-DA), identified lipids most
responsible for differences between fat-1 and WT sample groups.
Compounds were identified by database searches as performed by
Human Metabolome Database (HMDB) [19] and METLIN [20]
as well as by fragmentation patterns, retention times and ion-
mobility-derived collision cross sections versus commercially
available reference standards, when available. For the targeted
approach, mean concentrations and SEM values (n = 5) for each
group (fat-1 and WT) were calculated using appropriate internal
standards to normalize for variations in sample preparation and
MS detection. Univariate analyses (Student’s t-tests) were con-
ducted to assess for significance (p-value) and false-discovery rate
(FDR) was used to control for multiple comparison. A volcano plot
was produced to compare the fold-change versus the p-value for
the targeted lipids.
Data processing and analysis was conducted using Progenesis
QI Informatics (Nonlinear Dynamics, Newcastle, UK) and
MetaboAnalyst 2.0 [21]. Data quantification was performed using
TargetLynx software (Waters Corporation, Milford, Massachu-
setts USA).
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Results
To characterize the molecular phenotype associated with a
balanced omega-6/omega-3 ratio, a multi-platform lipidomic
approach was used (Figure 2). Plasma samples from the fat-1 and
WT groups were divided into two aliquots, one for an untargeted
lipidomic approach to screen for major lipid alterations, and the
other for a multiplexed targeted lipidomic approach to quantify
low-abundance, bioactive lipid species.
To identify the most abundant lipid alterations resulting from a
balanced omega-6/omega-3 tissue ratio, we adopted an untar-
geted lipidomic approach. Using electrospray-mass spectrometry
in both positive and negative ionization mode, we detected
thousands of molecular features in plasma samples. Significant
changes were identified using ANOVA (Table S3). Multivariate
statistics, including PCA (Figure S1) and PLS-DA, highlighted the
molecular features contributing most to the variance between the
two groups of mice (Figure 3A and B). A fold-change analysis
showed a marked increase in the levels of EPA and EPA-
containing cholesteryl ester (CE-EPA) (Figure 3C and D), whereas
a corresponding, significant decrease in the levels of omega-6 DPA
and DPA-containing CE (CE-omega-6-DPA) in fat-1 mice
compared to WT littermates (Figure 3C). Slight but significant
increases were also observed for unesterified DHA and CE-DHA,
accompanied by a modest decrease for unesterified AA and CE-
AA (Tables 1 and 2).
The plasma of fat-1 mice exhibited a balanced omega-6/omega-
3 ratio for unesterified PUFA, differing from the plasma of the WT
littermates, for which the ratio shifted toward the omega-6 PUFAs
Figure 2. Study design and workflow for the lipidomic analyses. Heterozygous female fat-1 and WT mice were fed a 6-month-long diet
containing 10% corn oil, which is particularly enriched in omega-6 PUFAs. Blood was collected and plasma samples were prepared and divided into
two aliquots. Before extraction, a mixture of internal standards was added to the plasma to normalize for variations in sample preparation or MS
detection. Complementary untargeted and targeted lipidomic analyses were conducted, and the results were integrated for the generation of a
unique lipidomic biosignature characteristic of the balanced omega-6/omega-3 ratio found in fat-1 mice.
doi:10.1371/journal.pone.0096221.g002
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(Table 1). Other significant differences between fat-1 and WT mice
include the levels of phosphatidylcholines (PCs) and phosphatidyl-
ethanolamines (PEs) (Figure 3B and Table S3). Most notably, we
observed a marked increase in the levels of various lysopho-
spholipids, including DHA-containing lyso PC and lyso PE, in fat-
1 mice (Figure 3B). Finally, the levels of various TG species
containing omega-6 fatty acids, as well as cholesterol and
cholesterol sulfate, were also decreased in fat-1 mice (Table S3).
PUFAs can be converted into hundreds of bioactive oxygenated
metabolites (i.e., oxylipins) by means of enzymatic and nonenzy-
matic reactions. To measure the levels of such usually low-
abundance metabolites, we used a multiplexed-targeted lipidomic
approach (Figure 2). We measured the levels of more than 100
common oxylipins using tandem MS (multiple reaction monitor-
ing). A volcano plot analysis using Student t-test p,0.01 and a fold
change .2 as cut-off parameters highlighted a marked increase in
the levels of EPA epoxides and diols in the plasma of fat-1 versus
WT mice, including 17(18)-epoxy-eicosatetraenoic acid (17(18)-
EpETE) and 17,18-dihydroxy-eicosatetraenoic acid (17,18-Di-
HETE) (Figure 4B). Such differences were found to be significant
after multiple comparison correction (Figure 4C and Table S1).
Minor increases were also observed for other EPA- or DHA-
derived metabolites (Figure 4C), whereas decreases were observed
in the levels of DGLA- and AA-derived metabolites in fat-1 mice
(Figure 4C and Table 1).
To determine the overall differences in the molecular pheno-
types of fat-1 and WT mice, we combined the results derived from
both the untargeted and targeted analyses. Correlation analysis
revealed a marked association of many features with EPA and
EPA metabolites (Figures 5A and B). Thes lipidomic biosignature
for fat-1 mice was underscored by a significant molecular contrast
between the two groups of mice (Figure 5C).
Figure 3. Untargeted lipidomic analysis. A, PLS-DA analysis showed a marked separation of plasma samples belonging to WT and fat-1 mice,
highlighting the features that contributed most to the variance between the two groups. B, Important features identified by PLS-DA. The colored
boxes on the right indicate the relative concentrations of the corresponding metabolite in each group under study. Variable Importance in Projection
(VIP) is a weighted sum of squares of the PLS loadings taking into account the amount of explained Y-variation in each dimension. C, Important
features selected by fold-change analysis (relative to WT) with threshold 2. The red circles represent features above the threshold. Note the values are
on log scale, so that both up-regulated and downregulated features can be plotted in a symmetrical way. D, Levels of EPA and percent composition
of CE-EPA in WT and fat-1 mice (n = 5, Student’s t test; ***, p,0.001). The data present the mean 6 SEM.
doi:10.1371/journal.pone.0096221.g003
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Discussion
In this study, we compared the plasma lipidome of transgenic
fat-1 and WT mice after exposing the animals for six months to a
diet high in omega-6 content. The fat-1 mice are able to
endogenously convert omega-6s into omega-3s, serving as a good
model of a balanced omega-6/omega-3 ratio [3,15,16]. The
design of this comparative study allowed an investigation of the
effects of long-term omega-3 PUFA enrichment without the need
for two different diets, thereby eliminating confounders derived
from differences in calories, flavor, or nutrients. Our approach also
avoided other confounders associated with individual genetic and
environmental variability, which can be found in nutritional
intervention studies involving human subjects [14,22].
Previous studies have determined the total fatty acid composi-
tion of various tissues from fat-1 mice using gas chromatography
(GC), showing that the omega-6/omega-3 PUFA ratio can range
from about 1 to 5 depending on the tissue, while wild type mice
usually range from 20–50 (with the exception of the brain which is
about 4) [3,15,16,22]. Such studies, however, aimed to measure
the total fatty acid content without detailing information on the
levels of unesterified fatty acids, their product of oxygenation
(oxylipins), and complex lipid species carrying PUFA, which may
be particularly enriched in the plasma lipoproteins of fasted
animals. By using two complementary analytical approaches,
untargeted and multiplexed targeted lipidomic analyses, we were
able to compare, in a more comprehensive fashion, the molecular
phenotypes of the plasma from fat-1 and WT mice. Indeed, our
study provided information about the availability of unesterified
fatty acids that might serve as precursors for the formation of
oxylipins. Furthermore, our study described the rearrangement of
fatty acyl chains in complex lipid structures, which might
determine 1) the physicochemical properties of the membranes
and lipoproteins containing such lipids and 2) the ability to
transport PUFAs to various organs [15,22].
The most obvious observation deriving from the untargeted
lipidomic analysis is a rearrangement of the fatty acyl chains of
CEs and phospholipids, which largely reflected the availability of
omega-3 and omega-6 PUFAs. Such results are consistent with
previous animal and human studies showing that blood lipid
composition reflects the intake of PUFAs [14,23–28]. We
observed, however, specific alterations of PUFA-containing lipids
that appear to be independent from the PUFA availability. In
particular, we observed a marked increase for CE-EPA in the
plasma of the fat-1 mice, as compared to CE-DHA (Table 2). This
observation generally aligns with previous reports showing a
Table 1. Levels of unesterified fatty acids (nmol/ml) in WT and fat-1 mice (n = 5).
Fatty acid species WT fat-1 p-value FDR
18:3 n-3 (ALA) 24.3361.49 24.4961.96 0.9484737 0.63176
20:5 n-3 (EPA) 2.1960.16 17.0460.36 2.558E-10 0.001165
22:5 n-3 (omega-3 DPA) 0.9660.09 3.3960.19 2.473E-06 0.009725
22:6 n-3 (DHA) 22.9261.68 27.1060.91 0.0017493 0.81954
Total n-3 50.4062.41 72.0262.54 0.0002642
18:2 n-6 (LA) 64.6467.42 50.0663.51 0.1135015 0.15112
20:3 n-6 (DGLA) 8.3260.74 7.0660.19 0.1382162 0.25896
20:4 n-6 (AA) 48.7266.21 34.6361.62 0.0596187 0.10569
22:4 n-6 (adrenic acid) 2.1060.13 1.5360.2 0.0440865 0.15112
22:5 n-6 (omega-6 DPA) 8.1660.6 3.1860.33 8.443E-05 0.009361
Total n-6 131.93613.35 96.4564.96 0.0374117
Omega-6/omega-3 ratio 2.6160.21 1.3460.04 0.0003226
P- values derived from Student’s t test. FDR, false discovery rate.
doi:10.1371/journal.pone.0096221.t001
Table 2. Composition (% of the total) of cholesteryl esters in WT and fat-1 mice (n = 5).
CE species WT fat-1 p-value FDR
18:3 n-3 1.1760.1 1.1660.03 0.8664 0.74976
20:5 n-3 0.3960.04 2.0860.27 0.0002 0.009725
22:5 n-3 1.0060.13 1.3660.11 0.039 0.008543
22:6 n-3 9.6660.63 12.7360.54 0.0054 0.58567
18:2 n-6 24.961.08 25.7261.08 0.4847 0.86083
20:3 n-6 7.9660.44 7.7560.29 0.6161 0.63176
20:4 n-6 50.9460.58 45.8161.49 0.009 0.42803
22:5 n-6 0.8260.07 0.2160.04 0.0001 0.008543
18:1 n-9 3.1860.6 3.1860.27 0.9351 0.77652
P-values derived from Student’s t test.
doi:10.1371/journal.pone.0096221.t002
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limited effect on CE-DHA concentration following supplementa-
tion with high doses of DHA in humans [29,30]. Although some
have speculated that a retroconversion of DHA to EPA could
contribute to the limited biosynthesis of CE-DHA [31–37], this
biosynthesis could also come about because of differential
specificity of enzymes involved in the metabolism of PC species
carrying DHA and EPA. Previous studies indeed showed that the
CE composition is largely determined by the specificity of the
enzyme lecithin-cholesterol acyl transferase (LCAT). The modest
changes observed for CE-DHA may therefore arise because DHA
is a poor substrate for LCAT, compared with EPA [26,38–41].
Although the literature included relatively little evidence regarding
the role of different cholesteryl esters, the observed increase in CE-
EPA might affect the size or action of lipoproteins [42,43].
Determining the plasma profile of unesterified fatty acids is
normally problematic due to the direct influence of diet on plasma
fatty acid content. Using a single diet for both WT and fat-1
animals made it possible for plasma content analysis to be used as
a reliable indicator of endogenous PUFA metabolism. Notably, the
diet does not contain longer chain PUFAs (such as AA, EPA, and
DHA) and any circulating lipids longer than 18 carbons must
come from endogenous metabolism of shorter PUFAs. Our study
highlighted a significant difference in the omega-6/omega-3 ratio
between unesterified plasma lipids and other previously reported
tissues [3,15,16]. In particular, our results showed a marked
increase for unesterified EPA compared to unesterified DHA in
the plasma of fat-1 mice (Table 1), which could be explained, in
part, by a retroconversion of DHA to EPA [31–37]. The
concomitant elevation of the DHA-containing phospholipids,
however, suggests that EPA might be a preferred substrate for
the hydrolytic activity of phospholipase A2 (PLA2) in plasma,
rather than DHA [44]. These observations point to a differential
metabolism for EPA and DHA, which could explain the diverse
physiological effects previously reported for these two omega-3
PUFAs [45–47]. On the other hand, DHA-containing phospho-
lipids and lysophospholipids may play roles in the cellular
membrane properties and in the transport of DHA to other
tissues [40,42]. Lysophospholipids containing DHA do, in fact,
appear to be best suited as carriers of this essential fatty acid to eye
and brain tissues, where it modulates the membrane fluidity of
synaptic vesicles [48–50] and displays neuroprotective properties
[51]. Notably, our untargeted analysis highlights a wide increase in
other lysophospholipid species, which comports with a previous
report showing that dietary supplementation with omega-3s can
dynamically regulate plasma lysoPC [52].
Figure 4. Targeted lipidomic analyses. A, Important features selected by volcano plot with fold change threshold (x) 2 and t-tests threshold (y)
0.1. The red circles represent features above the threshold. Note both fold changes (relative to WT) and p values are log transformed. The further its
position away from the (0,0), the more significant the feature is. B, Levels of representative EPA-derived epoxide and diol species in WT and fat-1 mice
(n = 5, Student’s t test; ***, p,0.001). The data present the mean 6 SEM. C, Most important oxylipins features as determined by volcano plot; also
reported: Student’s t test p-value, false discovery rate (FDR) and fold-change.
doi:10.1371/journal.pone.0096221.g004
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The untargeted lipidomic analysis also showed a significant
decrease in triacylglycerols and cholesterol. Such a decrease is in
accordance with the fact that the fat-1 phenotype is resistant to
metabolic syndrome, obesity, and liver steatosis [53–56]. Signif-
icantly, the unexpected decrease in cholesterol-sulfate in the
plasma of fat-1 mice may also be linked with some of the protective
effect of omega-3s. Cholesterol sulfate is present in lipoproteins,
and it has been found in atherosclerotic lesions of the human
aorta, where it plays a role in platelet adhesion, possibly
determining the prothrombotic potential of atherosclerotic lesions
[57]. Cholesterol sulfate is also found to be particularly enriched in
DHA-rich cellular membranes, where it seems to modulate the
lipid raft formation [58,59]. One might reasonably speculate that
the observed decrease in the circulating levels of cholesterol sulfate
might indicate the effect of possible sequestration caused by the
DHA-rich cellular membranes in fat-1 mice. To establish the
validity of such a hypothesis is beyond the scope of this paper.
The multiplexed targeted lipidomics experiments highlighted
the marked separation of the panel of oxylipins in the plasma of
WT and fat-1 mice. These lipid mediators are currently the focus
of considerable interest, for they are also key messengers for
cellular homeostasis, inflammation, platelet aggregation, and
vascularization [11–13]. Oxylipins are produced via enzymatic
or nonenzymatic oxygenation of both omega-6 and omega-3
PUFAs. Three major enzymatic pathways are involved in their
generation: cyclooxygenase (COX), lipoxygenase (LOX) and
cytochrome P450 (CYP) (Figures 6A and 6B). These pathways
are important drug targets for various diseases. The ability to
control such pathways with dietary interventions (i.e., omega-3
supplementation) could offset many of the side effects linked to
pharmacological treatments. Our study indicated that the
availability of unesterified omega-3 PUFA precursors correlated
with the increase in the levels of the corresponding omega-3
oxylipins while decreasing the omega-6 oxylipins. Such results
suggest that the higher levels of omega-3s compete with omega-6s
for enzymatic and nonenzymatic activities to ultimately reduce the
pro-inflammatory lipid mediators (HETEs, bicyclo-PGE2 and
(+/2)5-iPF2alpha-VI) while increasing the levels of anti-inflam-
matory mediators (5-HEPE, 15-HETrE, and 17-HDoHE).
Notably, the most abundant oxylipins alterations in fat-1 mice
were related to the metabolism of the CYP450 pathway [37]
(Figure 6). The CYP450 family of enzymes can produce epoxides
from PUFAs, which are subsequently metabolized by the soluble
epoxide hydrolase (sEH) to the corresponding vicinal diols,
dihydroxyeicosatrienoic acids [60]. In human and animal studies,
the CYP-dependent metabolite profiles were generally reflective of
the PUFA composition [14,37,61–63], suggesting that most of the
CYP-epoxygenases accept omega-3s and omega-6s as equally
efficient substrates [64]. Recent evidence shows that DHA intake
increases the levels of the EPA-derived vicinal diol 17,18-DiHETE
Figure 5. Lipidomic biosignature of fat-1mice. A, Correlation analysis was used to visualize the overall relationships between different features
and (B) to identify which features are correlated with EPA. C, Clustering result shown as heatmap (distance measure using Pearson, and clustering
algorithm using ward), providing an intuitive visualization of the characteristic lipidomic biosignature found in fat-1 mice versus WT mice. Each
colored cell on the map corresponds to a concentration value, with samples in rows and features/compounds in columns. Displayed are the top 25
lipids ranked by t-tests.
doi:10.1371/journal.pone.0096221.g005
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metabolized in the CYP/sEH pathway in plasma from piglets,
suggesting that DHA retroconversion to EPA may occur to some
extent [37].
Although the physiologic properties of AA-derived metabolites
of CYP have been studied extensively [65–67], the study of DHA
and EPA-derived metabolites of CYP450 and their physiologic
properties has only recently begun. Omega-3 CYP-metabolites
have been described as possessing anti-inflammatory [68] and
analgesic properties [69], as inhibitors of platelet aggregation [70],
and as pulmonary, smooth-muscle relaxants [71]. It has been
suggested that some of the beneficial effects of fish-oil-enhanced
diets on cardiovascular function may be mediated by the levels of
these metabolites [72]. Our results support the hypothesis that
CYP-450-mediated omega-3 metabolism might represent a major
physiological pathway underlying the reduced disease risk and
health benefits observed across numerous fat-1 mouse studies.
Finally, the integration of untargeted and targeted lipidomic
results provided a detailed molecular signature for a balanced
omega-6/omega-3 tissue ratio. Overall, EPA levels were the most
remarkable molecular change observed in the plasma of fat-1 mice.
Although the use of the fat-1 transgenic mouse model allowed us to
eliminate confounding factors of the diet, further work would be
needed to establish the validity of these molecular changes in
humans.
In conclusion, this study demonstrates a protective lipidomic
biosignature in fat-1 mice that may contribute to the low risk of
disease and health benefits associated with a balanced omega-6/
omega-3 tissue ratio. Such a lipidomic biosignature could be used
as a potential circulating biomarker for monitoring the ‘‘health
status’’ or the efficacy of nutritional intervention with omega-3s in
humans.
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